ADMA Q2 2026 net income $37.8M (+11% YoY); ASCENIV revenue $102.9M (+24% YoY)

ADMA BIOLOGICS, INC.

Total revenue $124.4M (+2% YoY); GAAP net income $37.8M (+11% YoY); GAAP basic EPS $0.17 (+17% YoY).
ASCENIV revenue $102.9M (+24% YoY); BIVIGAM revenue $19.4M (-49% YoY but sequential improvement from Q1 2026 trough).
Gross margin expanded to 69% from 55% YoY, driven by product mix shift toward higher-margin ASCENIV and yield-enhanced manufacturing.
Adjusted EBITDA $61.8M (+22% YoY); FY2026 guidance reiterated: revenue $530-560M, adj. EBITDA $265-300M.
Repurchased ~7.1M shares in Q2 (13.8M YTD, 5.3% of shares outstanding); SG-001 development on track for pre-IND submission by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.